Arbutus announces four abstracts accepted for AASLD, including AB-101 Poster of Distinction

Arbutus Biopharma Corp

Three abstracts on imdusiran and one on AB-101 accepted for AASLD Liver Meeting Nov 7-11, 2025 in Washington DC.
Imdusiran integrated safety analysis shows well-tolerated at 60-90 mg Q8W for up to 48 weeks dosing and follow-up.
Imdusiran may enhance pegylated interferon responsiveness in HBV genotype B/C patients vs historical data.
AB-101 up to 30 mg QD for 28 days was well tolerated; 83% mean PD-L1 receptor occupancy at 30 mg dose.
AB-101 abstract selected as Poster of Distinction; data on safety, PK, PD and HBV biomarkers will be presented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.